What You Should Know:
- PicnicHealth, a patient-centered health technology company, today announced its entry into the real-world data market for oncology.
- Drawing from its success working with chronic disease patients to create robust datasets, the company aims to advance oncology research using a similar model by working directly with people living with cancer to collect and structure their medical records data. PicnicHealth is actively exploring partnerships to develop new patient cohorts for several early-stage cancers including breast, colorectal, bladder, and prostate cancers, where real-world longitudinal datasets can help researchers understand and evaluate the impact of different interventions.
Data-Driven Advances Cancer Care
PicnicHealth also announced a multi-year partnership with AstraZeneca to advance real-world data development for early breast cancer (stages I-III). PicnicHealth will build an innovative registry to generate longitudinal real-world data from a cohort of consenting U.S. patients diagnosed with stage I-III breast cancers. The registry, which is open for enrollment, will empower participants by organizing and centralizing their complete medical record into an easy-to-use portal, while also enabling patients to contribute their de-identified data to advance breast cancer research.
Every year, more than 1.7 million people are diagnosed with cancer in the U.S. Advances in early detection and cancer treatment have helped improve overall survival rates for many cancers and have reduced annual U.S. cancer deaths to less than 600,000.
“The inherent strengths of PicnicHealth in organizing and synthesizing longitudinal patient journeys that span multiple health care providers and care sites make us an ideal partner to patients facing early-stage cancer diagnoses,” said Noga Leviner, CEO and Co-Founder, PicnicHealth. “Our partnership with AstraZeneca leverages the strengths of the PicnicHealth solution, as we will help collect and structure medical records data from the wide range of care experiences common in early breast cancer including primary care, surgery, radiology, and oncology along with patient-reported outcomes data.”